{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "231e890c",
   "metadata": {},
   "source": [
    "# Clinical Trials Participant Demographics - Asian Representation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "2febe061",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 150,
   "id": "aae7b6e6",
   "metadata": {},
   "outputs": [],
   "source": [
    "import numpy as np\n",
    "\n",
    "df = pd.read_csv('Clinical Trials Data, Compiled and Cleaned - [FDA] Drug Trials Snapshots_ All .csv')"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "c4e850f8",
   "metadata": {},
   "source": [
    "# Data Acquisition\n",
    "\n",
    "I chose the data set \"Clinical Trial Participation Demographics\" from ProPublica Data Store. This dataset displays a demographic breakdown of racial representation in clinical trials conducted for FDA-approved drugs between the time of January 2015 to June 2018. Here we have columns labeled: Brand Name, Indication, Women, White, Black or African American, Asian, All Other, Hispanic or Latino, US Only, Age ≥65, Age ≥75, Age ≥80, and Year.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "6151262a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>BRAND NAME</th>\n",
       "      <th>INDICATION</th>\n",
       "      <th>WOMEN</th>\n",
       "      <th>WHITE</th>\n",
       "      <th>BLACK OR AFRICAN AMERICAN</th>\n",
       "      <th>ASIAN</th>\n",
       "      <th>ALL OTHER (Aggregated):\\nAmerican Indian or Alaska Native (AI/AN), Native Hawaiian or Other Pacific Islander (NH/OPI), Unknown/Unreported</th>\n",
       "      <th>HISPANIC OR LATINO (2017 AND LATER ONLY)</th>\n",
       "      <th>UNITED STATES (2017 ONLY)</th>\n",
       "      <th>AGE\\n65 and OLDER</th>\n",
       "      <th>AGE\\n75 and OLDER</th>\n",
       "      <th>AGE\\n80 and OLDER</th>\n",
       "      <th>YEAR</th>\n",
       "      <th>NOTES</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>ADDYI</td>\n",
       "      <td>Treatment of acquired, generalized hypoactive ...</td>\n",
       "      <td>100%</td>\n",
       "      <td>89%</td>\n",
       "      <td>8%</td>\n",
       "      <td>1%</td>\n",
       "      <td>2%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0%</td>\n",
       "      <td>0%</td>\n",
       "      <td>0%</td>\n",
       "      <td>2015</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>ALECENSA</td>\n",
       "      <td>For the treatment of metastatic non-small cell...</td>\n",
       "      <td>55%</td>\n",
       "      <td>74%</td>\n",
       "      <td>2%</td>\n",
       "      <td>18%</td>\n",
       "      <td>7%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>14%</td>\n",
       "      <td>4%</td>\n",
       "      <td>&lt;1%</td>\n",
       "      <td>2015</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>ARISTADA</td>\n",
       "      <td>Treatment of schizophrenia</td>\n",
       "      <td>32%</td>\n",
       "      <td>47%</td>\n",
       "      <td>40%</td>\n",
       "      <td>13%</td>\n",
       "      <td>&lt;1%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0%</td>\n",
       "      <td>0%</td>\n",
       "      <td>0%</td>\n",
       "      <td>2015</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>AVYCAZ</td>\n",
       "      <td>Treatment of complicated intra-abdominal infec...</td>\n",
       "      <td>26%</td>\n",
       "      <td>60%</td>\n",
       "      <td>&lt;1%</td>\n",
       "      <td>27%</td>\n",
       "      <td>12%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>11%</td>\n",
       "      <td>8%</td>\n",
       "      <td>4%</td>\n",
       "      <td>2015</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>AVYCAZ</td>\n",
       "      <td>Treatment of complicated urinary tract infecti...</td>\n",
       "      <td>74%</td>\n",
       "      <td>60%</td>\n",
       "      <td>5%</td>\n",
       "      <td>10%</td>\n",
       "      <td>25%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>17%</td>\n",
       "      <td>4%</td>\n",
       "      <td>3%</td>\n",
       "      <td>2015</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  BRAND NAME                                         INDICATION WOMEN WHITE  \\\n",
       "0      ADDYI  Treatment of acquired, generalized hypoactive ...  100%   89%   \n",
       "1   ALECENSA  For the treatment of metastatic non-small cell...   55%   74%   \n",
       "2   ARISTADA                         Treatment of schizophrenia   32%   47%   \n",
       "3     AVYCAZ  Treatment of complicated intra-abdominal infec...   26%   60%   \n",
       "4     AVYCAZ  Treatment of complicated urinary tract infecti...   74%   60%   \n",
       "\n",
       "  BLACK OR AFRICAN AMERICAN ASIAN  \\\n",
       "0                        8%    1%   \n",
       "1                        2%   18%   \n",
       "2                       40%   13%   \n",
       "3                       <1%   27%   \n",
       "4                        5%   10%   \n",
       "\n",
       "  ALL OTHER (Aggregated):\\nAmerican Indian or Alaska Native (AI/AN), Native Hawaiian or Other Pacific Islander (NH/OPI), Unknown/Unreported  \\\n",
       "0                                                 2%                                                                                          \n",
       "1                                                 7%                                                                                          \n",
       "2                                                <1%                                                                                          \n",
       "3                                                12%                                                                                          \n",
       "4                                                25%                                                                                          \n",
       "\n",
       "  HISPANIC OR LATINO (2017 AND LATER ONLY) UNITED STATES (2017 ONLY)  \\\n",
       "0                                      NaN                       NaN   \n",
       "1                                      NaN                       NaN   \n",
       "2                                      NaN                       NaN   \n",
       "3                                      NaN                       NaN   \n",
       "4                                      NaN                       NaN   \n",
       "\n",
       "  AGE\\n65 and OLDER AGE\\n75 and OLDER AGE\\n80 and OLDER  YEAR NOTES  \n",
       "0                0%                0%                0%  2015   NaN  \n",
       "1               14%                4%               <1%  2015   NaN  \n",
       "2                0%                0%                0%  2015   NaN  \n",
       "3               11%                8%                4%  2015   NaN  \n",
       "4               17%                4%                3%  2015   NaN  "
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "15e51bbf",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "155\n"
     ]
    }
   ],
   "source": [
    "print(len(df))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "21cdaad7",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n"
     ]
    }
   ],
   "source": [
    "print(type(df))"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "0c17d8aa",
   "metadata": {},
   "source": [
    "These are the listed FDA-approved drugs given in the clinical trials under the column \"Brand Name\"."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "5cf11ad2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0          ADDYI\n",
       "1       ALECENSA\n",
       "2       ARISTADA\n",
       "3         AVYCAZ\n",
       "4         AVYCAZ\n",
       "         ...    \n",
       "150    TAVALISSE\n",
       "151      TIBSOVO\n",
       "152        TPOXX\n",
       "153     TROGARZO\n",
       "154       ZEMDRI\n",
       "Name: BRAND NAME, Length: 155, dtype: object"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['BRAND NAME']"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "46296e60",
   "metadata": {},
   "source": [
    "If we were to display the fifth row in the column \"Brand Name\" we're given the drug Bridion, this provides treatment for  the reversal of the effects of certain neuromuscular blocking agents."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "f6747e4c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'BRIDION'"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['BRAND NAME'][5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "7ce35197",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "BRAND NAME <class 'str'>\n",
      "INDICATION <class 'str'>\n",
      "WOMEN <class 'str'>\n",
      "WHITE <class 'str'>\n",
      "BLACK OR AFRICAN AMERICAN <class 'str'>\n",
      "ASIAN <class 'str'>\n",
      "ALL OTHER (Aggregated):\n",
      "American Indian or Alaska Native (AI/AN), Native Hawaiian or Other Pacific Islander (NH/OPI), Unknown/Unreported <class 'str'>\n",
      "HISPANIC OR LATINO (2017 AND LATER ONLY) <class 'float'>\n",
      "UNITED STATES (2017 ONLY) <class 'float'>\n",
      "AGE\n",
      "65 and OLDER <class 'str'>\n",
      "AGE\n",
      "75 and OLDER <class 'str'>\n",
      "AGE\n",
      "80 and OLDER <class 'str'>\n",
      "YEAR <class 'numpy.int64'>\n",
      "NOTES <class 'float'>\n"
     ]
    }
   ],
   "source": [
    "for col in df.columns:\n",
    "    print(col, type(df[col][0]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "70934cd5",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>YEAR</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>count</th>\n",
       "      <td>155.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>mean</th>\n",
       "      <td>2016.303226</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>std</th>\n",
       "      <td>1.141736</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>min</th>\n",
       "      <td>2015.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25%</th>\n",
       "      <td>2015.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50%</th>\n",
       "      <td>2016.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75%</th>\n",
       "      <td>2017.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>max</th>\n",
       "      <td>2018.000000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "              YEAR\n",
       "count   155.000000\n",
       "mean   2016.303226\n",
       "std       1.141736\n",
       "min    2015.000000\n",
       "25%    2015.000000\n",
       "50%    2016.000000\n",
       "75%    2017.000000\n",
       "max    2018.000000"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.describe()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "8948e837",
   "metadata": {},
   "source": [
    "# Data Processing\n",
    "Here we are cleaning the race column values that are originally strings `str`, in order to provide a visual we have to change the data type to a float value. We do this by converting our given percentages to decimals using the following code seen below. This step is repeated throughout the dataset for each race column, and included after is a bar graph (color coded for each race) displaying the racial representation of patients within the clinical trials."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 107,
   "id": "c977ee11",
   "metadata": {},
   "outputs": [],
   "source": [
    "df['ASIAN'] = df['ASIAN'].str.replace('<', '')\n",
    "df = df[df['ASIAN'] != 'NR']\n",
    "df['ASIAN'] = df['ASIAN'].str.rstrip('%').astype('float') / 100.0"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 148,
   "id": "51c99813",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1440x720 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "import matplotlib.patches as mpatches\n",
    "\n",
    "df.hist(column='ASIAN',color=\"#32a852\")\n",
    "colors = {'Asian Representation':'#32a852'}         \n",
    "labels = list(colors.keys())\n",
    "handles = [plt.Rectangle((0,0),1,1, color=colors[label]) for label in labels]\n",
    "plt.legend(handles, labels)\n",
    "plt.ylabel('Asian Clinical Patients')\n",
    "plt.xlabel('Percentages')\n",
    "plt.title('Asian Representation in Clinical Trials for FDA-approved Drugs')\n",
    "plt.rcParams[\"figure.figsize\"]=(20,10)\n",
    "\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 146,
   "id": "d6d5da68",
   "metadata": {},
   "outputs": [],
   "source": [
    "df['WHITE'] = df['WHITE'].str.replace('<', '')\n",
    "df = df[df['WHITE'] != 'NR']\n",
    "df['WHITE'] = df['WHITE'].str.rstrip('%').astype('float') / 100.0"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 147,
   "id": "aa632b9b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1440x720 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "\n",
    "df.hist(column='WHITE',color=\"#516f94\")\n",
    "colors = {'White Representation':'#516f94'}         \n",
    "labels = list(colors.keys())\n",
    "handles = [plt.Rectangle((0,0),1,1, color=colors[label]) for label in labels]\n",
    "plt.legend(handles, labels)\n",
    "plt.ylabel('White Clinical Patients')\n",
    "plt.xlabel('Percentages')\n",
    "plt.title('White Representation in Clinical Trials for FDA-approved Drugs')\n",
    "plt.rcParams[\"figure.figsize\"]=(20,10)\n",
    "\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 151,
   "id": "623e6205",
   "metadata": {},
   "outputs": [],
   "source": [
    "df['BLACK OR AFRICAN AMERICAN'] = df['BLACK OR AFRICAN AMERICAN'].str.replace('<', '')\n",
    "df = df[df['BLACK OR AFRICAN AMERICAN'] != 'NR']\n",
    "df['BLACK OR AFRICAN AMERICAN'] = df['BLACK OR AFRICAN AMERICAN'].str.rstrip('%').astype('float') / 100.0"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 152,
   "id": "5f4e928d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1440x720 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "\n",
    "df.hist(column='BLACK OR AFRICAN AMERICAN',color=\"#db56c5\")\n",
    "colors = {'Black or African American Representation':'#db56c5'}         \n",
    "labels = list(colors.keys())\n",
    "handles = [plt.Rectangle((0,0),1,1, color=colors[label]) for label in labels]\n",
    "plt.legend(handles, labels)\n",
    "plt.ylabel('Black/African American Clinical Patients')\n",
    "plt.xlabel('Percentages')\n",
    "plt.title('Black/African American Representation in Clinical Trials for FDA-approved Drugs')\n",
    "plt.rcParams[\"figure.figsize\"]=(20,10)\n",
    "\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 154,
   "id": "7702cc94",
   "metadata": {},
   "outputs": [],
   "source": [
    "df['ALL OTHER (Aggregated):\\nAmerican Indian or Alaska Native (AI/AN), Native Hawaiian or Other Pacific Islander (NH/OPI), Unknown/Unreported'] = df['ALL OTHER (Aggregated):\\nAmerican Indian or Alaska Native (AI/AN), Native Hawaiian or Other Pacific Islander (NH/OPI), Unknown/Unreported'].str.replace('<', '')\n",
    "df = df[df['ALL OTHER (Aggregated):\\nAmerican Indian or Alaska Native (AI/AN), Native Hawaiian or Other Pacific Islander (NH/OPI), Unknown/Unreported'] != 'NR']\n",
    "df['ALL OTHER (Aggregated):\\nAmerican Indian or Alaska Native (AI/AN), Native Hawaiian or Other Pacific Islander (NH/OPI), Unknown/Unreported'] = df['ALL OTHER (Aggregated):\\nAmerican Indian or Alaska Native (AI/AN), Native Hawaiian or Other Pacific Islander (NH/OPI), Unknown/Unreported'].str.rstrip('%').astype('float') / 100.0"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 155,
   "id": "d1e4cea9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1440x720 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "\n",
    "df.hist(column='ALL OTHER (Aggregated):\\nAmerican Indian or Alaska Native (AI/AN), Native Hawaiian or Other Pacific Islander (NH/OPI), Unknown/Unreported',color=\"#f5a849\")\n",
    "colors = {'All Other Racial Representation':'#f5a849'}         \n",
    "labels = list(colors.keys())\n",
    "handles = [plt.Rectangle((0,0),1,1, color=colors[label]) for label in labels]\n",
    "plt.legend(handles, labels)\n",
    "plt.ylabel('All Other Clinical Patients')\n",
    "plt.xlabel('Percentages')\n",
    "plt.title('All Other Racial Representation in Clinical Trials for FDA-approved Drugs')\n",
    "plt.rcParams[\"figure.figsize\"]=(20,10)\n",
    "\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7b911676",
   "metadata": {},
   "source": [
    "To specifically focus on the participation of Asian patients in these clinical trials, we drop columns pertaining to the data of other races (White, Black or African American, Hispanic, and All Other), gender (Women), and ages (Age ≥65, Age ≥75, Age ≥80) to narrow down our dataset. Doing so, cleans and organizes the dataset to clearly highlight the involvement of Asian patients. With the following code below, we select the certain columns we want to neglect and afterwards generate a new dataset with the remaining columns we wish to call attention to."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 115,
   "id": "3a9d0d0a",
   "metadata": {},
   "outputs": [],
   "source": [
    "data = pd.read_csv(\"Clinical Trials Data, Compiled and Cleaned - [FDA] Drug Trials Snapshots_ All .csv\", index_col =\"BRAND NAME\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 116,
   "id": "d80bbdae",
   "metadata": {},
   "outputs": [],
   "source": [
    "data.drop([\"WOMEN\", \"WHITE\",\"BLACK OR AFRICAN AMERICAN\",\"ALL OTHER (Aggregated):\\nAmerican Indian or Alaska Native (AI/AN), Native Hawaiian or Other Pacific Islander (NH/OPI), Unknown/Unreported\",\"HISPANIC OR LATINO (2017 AND LATER ONLY)\",\"UNITED STATES (2017 ONLY)\",\"AGE\\n65 and OLDER\",\"AGE\\n75 and OLDER\",\"AGE\\n80 and OLDER\"], axis = 1, inplace = True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 117,
   "id": "7f1c201f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>INDICATION</th>\n",
       "      <th>ASIAN</th>\n",
       "      <th>YEAR</th>\n",
       "      <th>NOTES</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>BRAND NAME</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>ADDYI</th>\n",
       "      <td>Treatment of acquired, generalized hypoactive ...</td>\n",
       "      <td>1%</td>\n",
       "      <td>2015</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>ALECENSA</th>\n",
       "      <td>For the treatment of metastatic non-small cell...</td>\n",
       "      <td>18%</td>\n",
       "      <td>2015</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>ARISTADA</th>\n",
       "      <td>Treatment of schizophrenia</td>\n",
       "      <td>13%</td>\n",
       "      <td>2015</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AVYCAZ</th>\n",
       "      <td>Treatment of complicated intra-abdominal infec...</td>\n",
       "      <td>27%</td>\n",
       "      <td>2015</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>AVYCAZ</th>\n",
       "      <td>Treatment of complicated urinary tract infecti...</td>\n",
       "      <td>10%</td>\n",
       "      <td>2015</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>TAVALISSE</th>\n",
       "      <td>Treatment of  adults with low platelet count d...</td>\n",
       "      <td>3%</td>\n",
       "      <td>2018</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>TIBSOVO</th>\n",
       "      <td>Treatment of adults with acute myeloid leukemi...</td>\n",
       "      <td>3%</td>\n",
       "      <td>2018</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>TPOXX</th>\n",
       "      <td>Treatment of smallpox disease</td>\n",
       "      <td>1%</td>\n",
       "      <td>2018</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>TROGARZO</th>\n",
       "      <td>Treatment of human immunodeficiency virus 1 (H...</td>\n",
       "      <td>10%</td>\n",
       "      <td>2018</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>ZEMDRI</th>\n",
       "      <td>Treatment of adults who have a complicated uri...</td>\n",
       "      <td>0%</td>\n",
       "      <td>2018</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>155 rows × 4 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                   INDICATION ASIAN  YEAR  \\\n",
       "BRAND NAME                                                                  \n",
       "ADDYI       Treatment of acquired, generalized hypoactive ...    1%  2015   \n",
       "ALECENSA    For the treatment of metastatic non-small cell...   18%  2015   \n",
       "ARISTADA                           Treatment of schizophrenia   13%  2015   \n",
       "AVYCAZ      Treatment of complicated intra-abdominal infec...   27%  2015   \n",
       "AVYCAZ      Treatment of complicated urinary tract infecti...   10%  2015   \n",
       "...                                                       ...   ...   ...   \n",
       "TAVALISSE   Treatment of  adults with low platelet count d...    3%  2018   \n",
       "TIBSOVO     Treatment of adults with acute myeloid leukemi...    3%  2018   \n",
       "TPOXX                           Treatment of smallpox disease    1%  2018   \n",
       "TROGARZO    Treatment of human immunodeficiency virus 1 (H...   10%  2018   \n",
       "ZEMDRI      Treatment of adults who have a complicated uri...    0%  2018   \n",
       "\n",
       "           NOTES  \n",
       "BRAND NAME        \n",
       "ADDYI        NaN  \n",
       "ALECENSA     NaN  \n",
       "ARISTADA     NaN  \n",
       "AVYCAZ       NaN  \n",
       "AVYCAZ       NaN  \n",
       "...          ...  \n",
       "TAVALISSE    NaN  \n",
       "TIBSOVO      NaN  \n",
       "TPOXX        NaN  \n",
       "TROGARZO     NaN  \n",
       "ZEMDRI       NaN  \n",
       "\n",
       "[155 rows x 4 columns]"
      ]
     },
     "execution_count": 117,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "1ae60d40",
   "metadata": {},
   "source": [
    "To better breakdown the data collected of the participation of Asian patients in certain FDA-approved drugs, we use the code `value_counts()` to describe what is the most frequently occurring element from our dataset (descending order). "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "id": "4fd7386a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0.01    22\n",
       "0.00    16\n",
       "0.03    16\n",
       "0.02     9\n",
       "0.04     9\n",
       "0.06     7\n",
       "0.08     6\n",
       "0.09     6\n",
       "0.12     5\n",
       "0.05     5\n",
       "0.07     4\n",
       "0.13     4\n",
       "0.21     4\n",
       "0.14     4\n",
       "0.10     4\n",
       "0.22     3\n",
       "0.17     3\n",
       "0.11     3\n",
       "0.18     3\n",
       "0.24     2\n",
       "0.16     2\n",
       "0.27     2\n",
       "0.33     2\n",
       "0.60     1\n",
       "0.35     1\n",
       "0.32     1\n",
       "0.31     1\n",
       "0.26     1\n",
       "0.20     1\n",
       "1.00     1\n",
       "0.59     1\n",
       "0.19     1\n",
       "0.47     1\n",
       "0.25     1\n",
       "Name: ASIAN, dtype: int64"
      ]
     },
     "execution_count": 72,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['ASIAN'].value_counts()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "b52acd25",
   "metadata": {},
   "source": [
    "From this, we can see that the most frequent involvement of Asian patients in these clinical trials has been a participation percentage of 1%. To simplify even more, we sort the dataset by just filtering out what drugs only had 1% of Asian representation. This is done so by performing the code block `df[df['ASIAN']==0.01]` seen below."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "id": "ec840abe",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>BRAND NAME</th>\n",
       "      <th>INDICATION</th>\n",
       "      <th>WOMEN</th>\n",
       "      <th>WHITE</th>\n",
       "      <th>BLACK OR AFRICAN AMERICAN</th>\n",
       "      <th>ASIAN</th>\n",
       "      <th>ALL OTHER (Aggregated):\\nAmerican Indian or Alaska Native (AI/AN), Native Hawaiian or Other Pacific Islander (NH/OPI), Unknown/Unreported</th>\n",
       "      <th>HISPANIC OR LATINO (2017 AND LATER ONLY)</th>\n",
       "      <th>UNITED STATES (2017 ONLY)</th>\n",
       "      <th>AGE\\n65 and OLDER</th>\n",
       "      <th>AGE\\n75 and OLDER</th>\n",
       "      <th>AGE\\n80 and OLDER</th>\n",
       "      <th>YEAR</th>\n",
       "      <th>NOTES</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>ADDYI</td>\n",
       "      <td>Treatment of acquired, generalized hypoactive ...</td>\n",
       "      <td>100%</td>\n",
       "      <td>89%</td>\n",
       "      <td>8%</td>\n",
       "      <td>0.01</td>\n",
       "      <td>2%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0%</td>\n",
       "      <td>0%</td>\n",
       "      <td>0%</td>\n",
       "      <td>2015</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>REXULTI</td>\n",
       "      <td>Treatment of major depressive disorder</td>\n",
       "      <td>69%</td>\n",
       "      <td>85%</td>\n",
       "      <td>12%</td>\n",
       "      <td>0.01</td>\n",
       "      <td>2%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>&lt;1%</td>\n",
       "      <td>0%</td>\n",
       "      <td>0%</td>\n",
       "      <td>2015</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>VELTASSA</td>\n",
       "      <td>Treatment of hyperkalemia</td>\n",
       "      <td>39%</td>\n",
       "      <td>99%</td>\n",
       "      <td>&lt;1%</td>\n",
       "      <td>0.01</td>\n",
       "      <td>&lt;1%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>61%</td>\n",
       "      <td>21%</td>\n",
       "      <td>4%</td>\n",
       "      <td>2015</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50</th>\n",
       "      <td>VIBERZI</td>\n",
       "      <td>Treatment of irritable bowel syndrome with dia...</td>\n",
       "      <td>66%</td>\n",
       "      <td>86%</td>\n",
       "      <td>12%</td>\n",
       "      <td>0.01</td>\n",
       "      <td>2%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10%</td>\n",
       "      <td>6%</td>\n",
       "      <td>&lt;1%</td>\n",
       "      <td>2015</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>58</th>\n",
       "      <td>ANTHIM</td>\n",
       "      <td>For the treatment of inhalational anthrax</td>\n",
       "      <td>46%</td>\n",
       "      <td>69%</td>\n",
       "      <td>28%</td>\n",
       "      <td>0.01</td>\n",
       "      <td>2%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>9%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2016</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>59</th>\n",
       "      <td>AXUMIN</td>\n",
       "      <td>Detection of prostate cancer recurrence</td>\n",
       "      <td>0%</td>\n",
       "      <td>31%</td>\n",
       "      <td>4%</td>\n",
       "      <td>0.01</td>\n",
       "      <td>64%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>66%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2016</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>70</th>\n",
       "      <td>OCALIVA</td>\n",
       "      <td>Treatment of primary biliary cholangitis in ad...</td>\n",
       "      <td>91%</td>\n",
       "      <td>94%</td>\n",
       "      <td>1%</td>\n",
       "      <td>0.01</td>\n",
       "      <td>3%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>19%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2016</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75</th>\n",
       "      <td>VENCLEXTA</td>\n",
       "      <td>Treatment of chronic lymphocytic leukemia (CLL)</td>\n",
       "      <td>31%</td>\n",
       "      <td>94%</td>\n",
       "      <td>3%</td>\n",
       "      <td>0.01</td>\n",
       "      <td>3%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>58%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2016</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>BEVYXXA</td>\n",
       "      <td>Prevention of venous thromboembolism</td>\n",
       "      <td>54%</td>\n",
       "      <td>93%</td>\n",
       "      <td>2%</td>\n",
       "      <td>0.01</td>\n",
       "      <td>5%</td>\n",
       "      <td>11%</td>\n",
       "      <td>7%</td>\n",
       "      <td>90%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>91</th>\n",
       "      <td>EMFLAZA</td>\n",
       "      <td>Treatment of Duchenne muscular dystrophy</td>\n",
       "      <td>0%</td>\n",
       "      <td>94%</td>\n",
       "      <td>0%</td>\n",
       "      <td>0.01</td>\n",
       "      <td>5%</td>\n",
       "      <td>NR</td>\n",
       "      <td>NR</td>\n",
       "      <td>0%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>IDHIFA</td>\n",
       "      <td>Treatment of relapsed acute myelogenous leukemia</td>\n",
       "      <td>49%</td>\n",
       "      <td>77%</td>\n",
       "      <td>6%</td>\n",
       "      <td>0.01</td>\n",
       "      <td>17%</td>\n",
       "      <td>9%</td>\n",
       "      <td>83%</td>\n",
       "      <td>60%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>97</th>\n",
       "      <td>INGREZZA</td>\n",
       "      <td>Treatment of tardive dyskinesia</td>\n",
       "      <td>42%</td>\n",
       "      <td>57%</td>\n",
       "      <td>39%</td>\n",
       "      <td>0.01</td>\n",
       "      <td>4%</td>\n",
       "      <td>28%</td>\n",
       "      <td>100%</td>\n",
       "      <td>18%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>113</th>\n",
       "      <td>SOLOSEC</td>\n",
       "      <td>Treatment of bacterial vaginosis</td>\n",
       "      <td>100%</td>\n",
       "      <td>46%</td>\n",
       "      <td>50%</td>\n",
       "      <td>0.01</td>\n",
       "      <td>3%</td>\n",
       "      <td>15%</td>\n",
       "      <td>100%</td>\n",
       "      <td>0%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>115</th>\n",
       "      <td>SYMPROIC</td>\n",
       "      <td>Treatment of opioid-induced constipation</td>\n",
       "      <td>62%</td>\n",
       "      <td>80%</td>\n",
       "      <td>18%</td>\n",
       "      <td>0.01</td>\n",
       "      <td>1%</td>\n",
       "      <td>8%</td>\n",
       "      <td>85%</td>\n",
       "      <td>15%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>122</th>\n",
       "      <td>VYZULTA</td>\n",
       "      <td>Treatment of glaucoma</td>\n",
       "      <td>58%</td>\n",
       "      <td>74%</td>\n",
       "      <td>24%</td>\n",
       "      <td>0.01</td>\n",
       "      <td>1%</td>\n",
       "      <td>12%</td>\n",
       "      <td>91%</td>\n",
       "      <td>52%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>127</th>\n",
       "      <td>AIMOVIG</td>\n",
       "      <td>Preventive treatment of migraine in adults</td>\n",
       "      <td>85%</td>\n",
       "      <td>91%</td>\n",
       "      <td>7%</td>\n",
       "      <td>0.01</td>\n",
       "      <td>1%</td>\n",
       "      <td>7%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>45%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2018</td>\n",
       "      <td>Note: Hispanic is one category out of: Hispani...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>128</th>\n",
       "      <td>AKYNZEO</td>\n",
       "      <td>Prevention of the nausea and vomiting that hap...</td>\n",
       "      <td>40%</td>\n",
       "      <td>100%</td>\n",
       "      <td>&lt;1%</td>\n",
       "      <td>0.01</td>\n",
       "      <td>1%</td>\n",
       "      <td>Not reported</td>\n",
       "      <td>NaN</td>\n",
       "      <td>32%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2018</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>139</th>\n",
       "      <td>LUCEMYRA</td>\n",
       "      <td>For the treatment of symptoms associated with ...</td>\n",
       "      <td>28%</td>\n",
       "      <td>67%</td>\n",
       "      <td>22%</td>\n",
       "      <td>0.01</td>\n",
       "      <td>11%</td>\n",
       "      <td>17%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>&lt;1%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2018</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>140</th>\n",
       "      <td>LUTATHERA</td>\n",
       "      <td>For the treatment of somatostatin receptor-pos...</td>\n",
       "      <td>49%</td>\n",
       "      <td>83%</td>\n",
       "      <td>4%</td>\n",
       "      <td>0.01</td>\n",
       "      <td>13%</td>\n",
       "      <td>3%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>51%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2018</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>146</th>\n",
       "      <td>ORILISSA</td>\n",
       "      <td>Treatment of moderate to severe pain associate...</td>\n",
       "      <td>100%</td>\n",
       "      <td>88%</td>\n",
       "      <td>9%</td>\n",
       "      <td>0.01</td>\n",
       "      <td>2%</td>\n",
       "      <td>14.70%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2018</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>149</th>\n",
       "      <td>SYMDEKO</td>\n",
       "      <td>For the treatment of cystic fibrosis</td>\n",
       "      <td>50%</td>\n",
       "      <td>97%</td>\n",
       "      <td>1%</td>\n",
       "      <td>0.01</td>\n",
       "      <td>2%</td>\n",
       "      <td>2.90%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2018</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>152</th>\n",
       "      <td>TPOXX</td>\n",
       "      <td>Treatment of smallpox disease</td>\n",
       "      <td>59%</td>\n",
       "      <td>69%</td>\n",
       "      <td>28%</td>\n",
       "      <td>0.01</td>\n",
       "      <td>2%</td>\n",
       "      <td>11%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2018</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    BRAND NAME                                         INDICATION WOMEN WHITE  \\\n",
       "0        ADDYI  Treatment of acquired, generalized hypoactive ...  100%   89%   \n",
       "38     REXULTI             Treatment of major depressive disorder   69%   85%   \n",
       "49    VELTASSA                          Treatment of hyperkalemia   39%   99%   \n",
       "50     VIBERZI  Treatment of irritable bowel syndrome with dia...   66%   86%   \n",
       "58      ANTHIM          For the treatment of inhalational anthrax   46%   69%   \n",
       "59      AXUMIN            Detection of prostate cancer recurrence    0%   31%   \n",
       "70     OCALIVA  Treatment of primary biliary cholangitis in ad...   91%   94%   \n",
       "75   VENCLEXTA    Treatment of chronic lymphocytic leukemia (CLL)   31%   94%   \n",
       "87     BEVYXXA               Prevention of venous thromboembolism   54%   93%   \n",
       "91     EMFLAZA           Treatment of Duchenne muscular dystrophy    0%   94%   \n",
       "95      IDHIFA   Treatment of relapsed acute myelogenous leukemia   49%   77%   \n",
       "97    INGREZZA                    Treatment of tardive dyskinesia   42%   57%   \n",
       "113    SOLOSEC                   Treatment of bacterial vaginosis  100%   46%   \n",
       "115   SYMPROIC           Treatment of opioid-induced constipation   62%   80%   \n",
       "122    VYZULTA                              Treatment of glaucoma   58%   74%   \n",
       "127    AIMOVIG         Preventive treatment of migraine in adults   85%   91%   \n",
       "128    AKYNZEO  Prevention of the nausea and vomiting that hap...   40%  100%   \n",
       "139   LUCEMYRA  For the treatment of symptoms associated with ...   28%   67%   \n",
       "140  LUTATHERA  For the treatment of somatostatin receptor-pos...   49%   83%   \n",
       "146   ORILISSA  Treatment of moderate to severe pain associate...  100%   88%   \n",
       "149    SYMDEKO               For the treatment of cystic fibrosis   50%   97%   \n",
       "152      TPOXX                      Treatment of smallpox disease   59%   69%   \n",
       "\n",
       "    BLACK OR AFRICAN AMERICAN  ASIAN  \\\n",
       "0                          8%   0.01   \n",
       "38                        12%   0.01   \n",
       "49                        <1%   0.01   \n",
       "50                        12%   0.01   \n",
       "58                        28%   0.01   \n",
       "59                         4%   0.01   \n",
       "70                         1%   0.01   \n",
       "75                         3%   0.01   \n",
       "87                         2%   0.01   \n",
       "91                         0%   0.01   \n",
       "95                         6%   0.01   \n",
       "97                        39%   0.01   \n",
       "113                       50%   0.01   \n",
       "115                       18%   0.01   \n",
       "122                       24%   0.01   \n",
       "127                        7%   0.01   \n",
       "128                       <1%   0.01   \n",
       "139                       22%   0.01   \n",
       "140                        4%   0.01   \n",
       "146                        9%   0.01   \n",
       "149                        1%   0.01   \n",
       "152                       28%   0.01   \n",
       "\n",
       "    ALL OTHER (Aggregated):\\nAmerican Indian or Alaska Native (AI/AN), Native Hawaiian or Other Pacific Islander (NH/OPI), Unknown/Unreported  \\\n",
       "0                                                   2%                                                                                          \n",
       "38                                                  2%                                                                                          \n",
       "49                                                 <1%                                                                                          \n",
       "50                                                  2%                                                                                          \n",
       "58                                                  2%                                                                                          \n",
       "59                                                 64%                                                                                          \n",
       "70                                                  3%                                                                                          \n",
       "75                                                  3%                                                                                          \n",
       "87                                                  5%                                                                                          \n",
       "91                                                  5%                                                                                          \n",
       "95                                                 17%                                                                                          \n",
       "97                                                  4%                                                                                          \n",
       "113                                                 3%                                                                                          \n",
       "115                                                 1%                                                                                          \n",
       "122                                                 1%                                                                                          \n",
       "127                                                 1%                                                                                          \n",
       "128                                                 1%                                                                                          \n",
       "139                                                11%                                                                                          \n",
       "140                                                13%                                                                                          \n",
       "146                                                 2%                                                                                          \n",
       "149                                                 2%                                                                                          \n",
       "152                                                 2%                                                                                          \n",
       "\n",
       "    HISPANIC OR LATINO (2017 AND LATER ONLY) UNITED STATES (2017 ONLY)  \\\n",
       "0                                        NaN                       NaN   \n",
       "38                                       NaN                       NaN   \n",
       "49                                       NaN                       NaN   \n",
       "50                                       NaN                       NaN   \n",
       "58                                       NaN                       NaN   \n",
       "59                                       NaN                       NaN   \n",
       "70                                       NaN                       NaN   \n",
       "75                                       NaN                       NaN   \n",
       "87                                       11%                        7%   \n",
       "91                                        NR                        NR   \n",
       "95                                        9%                       83%   \n",
       "97                                       28%                      100%   \n",
       "113                                      15%                      100%   \n",
       "115                                       8%                       85%   \n",
       "122                                      12%                       91%   \n",
       "127                                       7%                       NaN   \n",
       "128                             Not reported                       NaN   \n",
       "139                                      17%                       NaN   \n",
       "140                                       3%                       NaN   \n",
       "146                                   14.70%                       NaN   \n",
       "149                                    2.90%                       NaN   \n",
       "152                                      11%                       NaN   \n",
       "\n",
       "    AGE\\n65 and OLDER AGE\\n75 and OLDER AGE\\n80 and OLDER  YEAR  \\\n",
       "0                  0%                0%                0%  2015   \n",
       "38                <1%                0%                0%  2015   \n",
       "49                61%               21%                4%  2015   \n",
       "50                10%                6%               <1%  2015   \n",
       "58                 9%               NaN               NaN  2016   \n",
       "59                66%               NaN               NaN  2016   \n",
       "70                19%               NaN               NaN  2016   \n",
       "75                58%               NaN               NaN  2016   \n",
       "87                90%               NaN               NaN  2017   \n",
       "91                 0%               NaN               NaN  2017   \n",
       "95                60%               NaN               NaN  2017   \n",
       "97                18%               NaN               NaN  2017   \n",
       "113                0%               NaN               NaN  2017   \n",
       "115               15%               NaN               NaN  2017   \n",
       "122               52%               NaN               NaN  2017   \n",
       "127               45%               NaN               NaN  2018   \n",
       "128               32%               NaN               NaN  2018   \n",
       "139               <1%               NaN               NaN  2018   \n",
       "140               51%               NaN               NaN  2018   \n",
       "146                0%               NaN               NaN  2018   \n",
       "149               NaN               NaN               NaN  2018   \n",
       "152               10%               NaN               NaN  2018   \n",
       "\n",
       "                                                 NOTES  \n",
       "0                                                  NaN  \n",
       "38                                                 NaN  \n",
       "49                                                 NaN  \n",
       "50                                                 NaN  \n",
       "58                                                 NaN  \n",
       "59                                                 NaN  \n",
       "70                                                 NaN  \n",
       "75                                                 NaN  \n",
       "87                                                 NaN  \n",
       "91                                                 NaN  \n",
       "95                                                 NaN  \n",
       "97                                                 NaN  \n",
       "113                                                NaN  \n",
       "115                                                NaN  \n",
       "122                                                NaN  \n",
       "127  Note: Hispanic is one category out of: Hispani...  \n",
       "128                                                NaN  \n",
       "139                                                NaN  \n",
       "140                                                NaN  \n",
       "146                                                NaN  \n",
       "149                                                NaN  \n",
       "152                                                NaN  "
      ]
     },
     "execution_count": 78,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[df['ASIAN']==0.01]"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "eaa7333a",
   "metadata": {},
   "source": [
    "To again display a clean and overall better dataset that clearly shows what drugs only contain 1% of Asian representation we create a new variable named `asian_below`. Within the variable, we filter the columns to only include \"Brand Name\" (list of FDA-approved drugs) and \"Asian\" (which are set to display just the value of 0.01 or 1%)."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 118,
   "id": "b5ddcf4a",
   "metadata": {},
   "outputs": [],
   "source": [
    "asian_below=df[df['ASIAN']==0.01]\n",
    "asian_below=asian_below[['BRAND NAME','ASIAN']]"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ebe67bec",
   "metadata": {},
   "source": [
    "# Data Analysis\n",
    "After running the code block above, we're presented this dataset with just the drug names of which only contained 1% of Asian participation. In total we have 20 FDA-approved drugs that satisfy this condition. "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 119,
   "id": "fdd7193e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>BRAND NAME</th>\n",
       "      <th>ASIAN</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>ADDYI</td>\n",
       "      <td>0.01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>REXULTI</td>\n",
       "      <td>0.01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>VELTASSA</td>\n",
       "      <td>0.01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50</th>\n",
       "      <td>VIBERZI</td>\n",
       "      <td>0.01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>58</th>\n",
       "      <td>ANTHIM</td>\n",
       "      <td>0.01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>59</th>\n",
       "      <td>AXUMIN</td>\n",
       "      <td>0.01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>70</th>\n",
       "      <td>OCALIVA</td>\n",
       "      <td>0.01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75</th>\n",
       "      <td>VENCLEXTA</td>\n",
       "      <td>0.01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>BEVYXXA</td>\n",
       "      <td>0.01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>91</th>\n",
       "      <td>EMFLAZA</td>\n",
       "      <td>0.01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>IDHIFA</td>\n",
       "      <td>0.01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>97</th>\n",
       "      <td>INGREZZA</td>\n",
       "      <td>0.01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>113</th>\n",
       "      <td>SOLOSEC</td>\n",
       "      <td>0.01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>115</th>\n",
       "      <td>SYMPROIC</td>\n",
       "      <td>0.01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>122</th>\n",
       "      <td>VYZULTA</td>\n",
       "      <td>0.01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>127</th>\n",
       "      <td>AIMOVIG</td>\n",
       "      <td>0.01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>128</th>\n",
       "      <td>AKYNZEO</td>\n",
       "      <td>0.01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>139</th>\n",
       "      <td>LUCEMYRA</td>\n",
       "      <td>0.01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>140</th>\n",
       "      <td>LUTATHERA</td>\n",
       "      <td>0.01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>146</th>\n",
       "      <td>ORILISSA</td>\n",
       "      <td>0.01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>149</th>\n",
       "      <td>SYMDEKO</td>\n",
       "      <td>0.01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>152</th>\n",
       "      <td>TPOXX</td>\n",
       "      <td>0.01</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    BRAND NAME  ASIAN\n",
       "0        ADDYI   0.01\n",
       "38     REXULTI   0.01\n",
       "49    VELTASSA   0.01\n",
       "50     VIBERZI   0.01\n",
       "58      ANTHIM   0.01\n",
       "59      AXUMIN   0.01\n",
       "70     OCALIVA   0.01\n",
       "75   VENCLEXTA   0.01\n",
       "87     BEVYXXA   0.01\n",
       "91     EMFLAZA   0.01\n",
       "95      IDHIFA   0.01\n",
       "97    INGREZZA   0.01\n",
       "113    SOLOSEC   0.01\n",
       "115   SYMPROIC   0.01\n",
       "122    VYZULTA   0.01\n",
       "127    AIMOVIG   0.01\n",
       "128    AKYNZEO   0.01\n",
       "139   LUCEMYRA   0.01\n",
       "140  LUTATHERA   0.01\n",
       "146   ORILISSA   0.01\n",
       "149    SYMDEKO   0.01\n",
       "152      TPOXX   0.01"
      ]
     },
     "execution_count": 119,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "asian_below"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "df3273fc",
   "metadata": {},
   "source": [
    "These drugs range from treatment of smallpox disease to cystic fibrosis to migraine prevention. With this information portraying what drugs have little usage/participation from Asian patients (1%), another study could be conducted to understand and conclude what health problems are of more concern for certain racial communities. "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 156,
   "id": "0560ce80",
   "metadata": {},
   "outputs": [],
   "source": [
    "asian_below.to_csv('Clinical Trial Participant Demographics - Asian Representation')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "2ed60a0e",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
